Articles by Emily Menendez
Early phase I data on 177Lu rhPSMA-10.1 has demonstrated an encouraging safety profile for the novel radioligand therapy.
Patients were guided through a VR experience to view their specific anatomy in a 3-dimensional space.
Immunotherapy is often used for metastatic disease, yet it is still under investigation in neoadjuvant and adjuvant settings.
Cohort 2 of TROPHY-U-01 showed that sacituzumab govitecan monotherapy can benefit cisplatin-ineligible patients.
Olaparib monotherapy can provide high and durable PSA50 response rates in patients with PCa and BRCA2 alterations.
Enzalutamide was associated with improvements in OS, PCS, TTS, and TTR compared with abiraterone acetate.
If approved, mitomycin is anticipated to become the first FDA-approved treatment for LG-IR-NMIBC.
Stockholm3 is a blood-based test for the detection of prostate cancer that has demonstrated beneficial detection rates.
For patients with UTUC, bladder cuff excision and radical nephroureterectomy is a longstanding treatment.
Multiple cycles of AcPSMA can cause side effects including salivary gland toxicity and xerostomia.
The impact of potential comorbidities and concomitant medication interactions in ARPIs are not well understood.
Paclitaxel, ifosfamide, and cisplatin is a combination commonly used for the treatment of germ cell tumors.
BCG is ineffective in 30% to 77% of patients, and many experience disease recurrence within 5 years.
The genetic basis of HER2 overexpression other than ERBB2 amplification in UC is not well understood.
CEUS for the assessment of nccRCC can provide a more sensitive alternative to conventional ultrasound imaging.
PSMA PET/CT can act as a better alternative to MRI, but research on second-generation PSMA PET radioligands is limited.
About 1 in 12 patients who undergo non-targeted prostate biopsy with a result of GGG 1 PC may have more aggressive cancer.
Darolutamide plus ADT provided a clinically meaningful increase in rPFS compared with placebo plus ADT.
Patients with localized UTUC have high unmet needs and tumors with a high frequency of FGFR3 alterations.
Abiraterone acetate, prednisone, and apalutamide is a common combination treatment for mCRPC.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.